10x Genomics, Inc. (TXG) Market Cap & Valuation Ratios
10x Genomics, Inc. (TXG) has a market cap of $9.3B and a price-to-sales ratio of 15.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TXG10x Genomics, Inc.Follow TXG — free
—
Price chart with a free account
- Market cap
- 9.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
health information services · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| TXG | 9.3 | — | 14.2 | — | 1.3% | -4% | -14% | -25% |
| VEEV | 52 | 52.9 | 13.0 | 41.9 | 3.1% | +17% | 30% | 15% |
| TEM | 12 | — | 9.1 | — | -2.2% | +50% | -20% | -23% |
| BTSG | 12 | 36.2 | 0.9 | 22.2 | 3.4% | +26% | 3% | 10% |
| HNGE | 9.0 | 86.4 | 12.0 | 87.5 | 3.2% | +50% | 13% | 158% |
| HQY | 8.6 | 37.5 | 6.8 | 18.2 | 5.1% | +7% | 26% | 10% |
| DOCS | 6.0 | 39.3 | 8.7 | 27.3 | 4.9% | +11% | 30% | 19% |
| WAY | 5.5 | 41.2 | 5.6 | 15.7 | 4.5% | +19% | 23% | 4% |
| HTFL | 4.9 | — | 22.5 | — | -1.2% | +43% | -38% | -33% |
| PRVA | 2.9 | 106.7 | 1.0 | 43.0 | 4.6% | +24% | 2% | 8% |
| OMCL | 1.7 | — | 1.3 | 11.9 | 7.4% | +8% | 5% | 3% |
| Median of these 10 | 41.2 | 7.8 | 24.8 | 3.9% | +22% | 9% | 9% |
; EV/Sales 14.2 vs. 7.8.
Growth vs. price
each dot a company · hover or tap for valuesTXG and TEM and HTFL and OMCL have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
10x Genomics, Inc. — questions
- What is 10x Genomics, Inc.'s market cap?
- $9.3B.
- What is 10x Genomics, Inc.'s price-to-sales ratio?
- 15.1.
Every figure on this page comes from 10x Genomics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.